ArticleInfluenza and other respiratory viruses2026
Early COVID-19 and Severity of Subsequent Omicron Infection in Ontario Canada.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early COVID-19 and Severity of Subsequent Omicron Infection in Ontario Canada.Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
We evaluated whether having early COVID-19 reduced the severity of subsequent Omicron infection, assessing activities of daily living (ADL), healthcare utilization and illness duration. Comparisons were made between persons with (1) early COVID-19-compatible illness with a negative test, (2) early lab-confirmed SARS-CoV-2 14-26 months and (3) early lab-confirmed SAR-CoV-2 > 26 months before Omicron infection. Among 261 patients with laboratory-confirmed Omicron, 177 (68%) had COVID-19 in 2020, a median of 793 days (IQR, 659-902) prior to Omicron infection. Compared to no early COVID-19, COVID-19 14-26 months, but not > 26 months, before was associated with reduced impact on ADL during first Omicron infection (OR 0.52, 95% CI 0.29-0.93).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.